Centricity Research has acquired North Carolina-based Lucas Research, making it the fifth clinical research company to join Centricity since it launched in November 2021.
With this acquisition, Centricity now has more than 35 clinical research sites, reaching 8.5 million geographically and ethnically-diverse patients. The company has 155 investigators who perform trials in around 20 therapeutic areas, including infectious disease, neurology, endocrinology, oncology, cardiology, dermatology and vaccines.
“We’re thrilled to combine forces with the phenomenal team at Lucas Research, which will help strengthen our Phase I clinical trial capabilities, geographic reach, and operational expertise as we forge ahead with our mission to advance medical knowledge and develop better medications,” said Dr Jeff Kingsley, Chief Corporate Development Officer of Centricity Research.
Founded in 2004 as a hybrid clinical research organisation and medical practice, Lucas Research specialises in immunology, inflammation, diabetes, weight loss and other endocrine diseases.
“We will continue to offer our patients world class care, but now with the extensive resources of an international team to ensure that we are delivering the top advances in care,” said Lucas Research Principal Investigator Dr Jeannie Lucas, who co-founded the company with her husband, CEO Seth Medlin.